In this paper we will discuss about Pan Genetics BV’s current business deal. The company announced, in March 2008, that it would receive 23 million dollar investment from Edmond de Rothschild Investment Partners. There are five more investors involved in this deal.
The money will be used by Pan Genetics to fund their upcoming research programs. Pan Genetics BV’s recent business deal with Edmond de Rothschild Investment Partners was disclosed in March 2008. The former will get a 23 million dollar investment from the latter. The other investors are Fortis Private Equity, Biogen Idec New Ventures, Index Ventures, Credit Agricole Private Equity and Forbion Capital Partners.
PanGenetics is situated in Netherlands. It develops therapeutic antibodies from the final stage of research through to the “clinical proof of concept”. It has also another office in Cambridge, UK.
Edmond de Rothschild Investment Partners, situated in Paris, mainly invests in the private companies. Its current amount of capital is 500 million euros.
The company’s life science team consists of 6 members who have cumulatively more than 80 years of relevant experience. Edmond de Rothschild is affiliated with La Compagnie Financie Edmond de Rothschild.
Biogen Idec New Ventures, based in the United States of America, is a corporate venture group of Biogen Idec. It was established in 2004 with an aim of investing more than 100 million dollars in the biotech industries.
On the other hand, Fortis Private Equity, which is a subsidiary of Fortis Merchant Banking, supervises all the private equity assets of Fortis, while, Index Ventures, established in 1996, is a premier venture capital firm of Switzerland. It mainly focuses on the Life Science and IT sectors.
Forbion Capital Partners mainly invests in the health companies of Europe and the United States of America who develop world-class technologies and medical products. The Forbion team has already invested in more than 37 drug development companies since its establishment in 2000.
Credit Agricole Private Equity is an investment management company, authorized by the AMF, and a fully owned division of Credit Agricole S.A. It focuses mainly on the direct private equity investments.
This deal will help Pan Genetics to accelerate its two therapeutic antibody development programs, namely, PG110 and PG102.